Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis
Progressive(PGR) Prnewswire·2024-08-13 04:05Progressive(PGR) Prnewswire·2024-08-13 04:05
R1Progressive(PGR) Prnewswire·2024-08-13 04:05